- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06565052
Virkningen af præoperativ træning og ernæringsoptimering på perioperative resultater for patienter, der gennemgår behandling for rektalcancer: PROPEL-forsøget
The purpose of this study is to determine the feasibility of a prehabilitation program for participants diagnosed with rectal cancer undergoing neoadjuvant chemotherapy and/or radiation, followed by surgical resection.
The names of the groups in this research study are:
- Group A: Prehabilitation program
- Group B: Usual Care
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
This is a non-blinded, randomized control trial to determine the feasibility of a hybrid-model, prehabilitation program for participants diagnosed with rectal cancer undergoing neoadjuvant therapy (chemotherapy and/or radiation) before surgical resection. Investigators hope that prehabilitation will result in improved outcomes after surgery.
Participants will be randomized into one of the study groups: Group A: prehabilitation program, or Group B: usual care. Randomization means that a participant is placed into a group by chance.
The research study procedures include screening for eligibility, in-clinic visits, physical exams, exercise training, blood tests, and questionnaires.
It is expected that about 40 participants will take part in this research study.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Jeffrey Meyerhardt, MD, MPH
- Telefonnummer: 617-632-6855
- E-mail: jeffrey_meyerhardt@dfci.harvard.edu
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Rekruttering
- Brigham and Women's Hospital
-
Kontakt:
- Joel Goldberg, MD
- Telefonnummer: 617-732-8460
- E-mail: JGOLDBERG1@PARTNERS.ORG
-
Ledende efterforsker:
- Joel Goldberg, MD
-
Boston, Massachusetts, Forenede Stater, 02115
- Rekruttering
- Dana-Farber Cancer Institute
-
Ledende efterforsker:
- Jeffrey Meyerhardt, MD
-
Kontakt:
- Jeffrey Meyerhardt, MD, MPH
- Telefonnummer: 617-632-6855
- E-mail: jeffrey_meyerhardt@dfci.harvard.edu
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age greater than or equal to 18 years at time of enrollment.
- English-Speaking.
- Diagnosis of clinical stage II-III rectal cancer.
- Planned, ongoing or just completed neoadjuvant treatment, including either 1) chemoradiation, 2) total neoadjuvant therapy (TNT), or 3) chemotherapy only; and anticipated surgical resection to follow.
- Able to understand the study procedures, agree to participate in the study program, and voluntarily provide informed consent.
Exclusion Criteria:
- Distant metastatic disease known at the time of diagnosis.
- Functional incapacity (i.e., incapable of performing exercise testing).
- Comorbid conditions or cognitive/physical impairments that contraindicate exercise.
- Currently undergoing treatment for a secondary primary tumor, in addition to primary rectal cancer.
- Currently enrolled in a separate clinical trial that would prohibit them from performing the tasks instructed in this trial.
- Currently participating in more than 60 minutes of moderate-to-vigorous aerobic exercise per week over the past month. This study targets insufficiently active persons to assess the effect of the described intervention, where additional exercise done regularly will contaminate the intervention effects.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Group A: Prehabilitation Program
Participants will be randomized in a 1:1 ratio using a permuted blocked design and stratified by neoadjuvant therapy received. Participants will complete the following:
|
A hybrid-based, prehabilitation regimen comprised of nutritional optimization (multivitamin and protein supplement shake) and virtual, aerobic and resistance exercise sessions with clinical exercise physiologists. Virtual exercise sessions will be performed via a HIPAA-compliant videoconferencing platform or by phone call. Mini-exercise cycle ergometer, dumbbells, and resistance bands will be provided and delivered to participant. Heart rate monitors and wi-fi enable tablet will be provided if needed. |
|
Ingen indgriben: Group B: Usual Care
Participants will be randomized in a 1:1 ratio using a permuted blocked design and stratified by neoadjuvant therapy received. Participants will complete the following:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Enrollment Rate
Tidsramme: Baseline
|
The proportion of eligible individuals that are enrolled to the study. Feasibility of the intervention is defined as an enrollment rate of greater than 10% of approached, eligible participants. |
Baseline
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Adherence Rate to the Prehabilitation Program
Tidsramme: At post-intervention (approximately Week 4)
|
The number of intervention assessments completed by participants in Group A. Feasibility of the intervention is defined as at least 50% of participants adhering to at least 50% of the prescribed assessments of the prehabilitation program. |
At post-intervention (approximately Week 4)
|
|
Completion Rate of Physical Function Testing (Group A)
Tidsramme: At post-intervention (approximately Week 4)
|
Defined as the number of testing assessments (resting blood pressure, measure of cardiorespiratory fitness, Short Physical Performance Battery, muscular strength, and anthropometric measures) completed by participants. |
At post-intervention (approximately Week 4)
|
|
Completion Rate of Physical Function Testing (Group B)
Tidsramme: At post-intervention (approximately Week 4)
|
Defined as the number of testing assessments (resting blood pressure, measure of cardiorespiratory fitness, Short Physical Performance Battery, muscular strength, and anthropometric measures) completed by participants. |
At post-intervention (approximately Week 4)
|
|
Completion Rate of Questionnaire Assessments
Tidsramme: At baseline and the postoperative visit (approximately Week 9)
|
Defined as the number of questionnaires completed by all participants. |
At baseline and the postoperative visit (approximately Week 9)
|
|
Participant Fall Rate (Group A)
Tidsramme: At post-intervention (approximately Week 4)
|
Defined as the number of falls attributable to the exercise and nutrition components of the intervention. |
At post-intervention (approximately Week 4)
|
|
Participant Fall Rate (Group B)
Tidsramme: At post-intervention (approximately Week 4)
|
Defined as the number of falls attributable to the exercise and nutrition components of the intervention. |
At post-intervention (approximately Week 4)
|
|
Rate of Hospitalization (Group A)
Tidsramme: At post-intervention (approximately Week 4)
|
Defined as the number of hospitalizations attributable to the exercise and nutrition components of the intervention. |
At post-intervention (approximately Week 4)
|
|
Rate of Hospitalization (Group B)
Tidsramme: At post-intervention (approximately Week 4)
|
Defined as the number of hospitalizations attributable to the exercise and nutrition components of the intervention. |
At post-intervention (approximately Week 4)
|
|
Rate of Musculoskeletal Injury (Group A)
Tidsramme: At post-intervention (approximately Week 4)
|
Defined as the number of musculoskeletal injuries attributable to the exercise and nutrition components of the intervention. |
At post-intervention (approximately Week 4)
|
|
Rate of Musculoskeletal Injury (Group B)
Tidsramme: At post-intervention (approximately Week 4)
|
Defined as the number of musculoskeletal injuries attributable to the exercise and nutrition components of the intervention. |
At post-intervention (approximately Week 4)
|
|
Change in Resting Blood Pressure from Baseline to Post-Intervention
Tidsramme: From baseline to post-operative visit (approximately week 9)
|
Assessed by resting blood pressure. The average systolic blood pressure (of two measurements from each arm) will be recorded. |
From baseline to post-operative visit (approximately week 9)
|
|
Change in Cardiorespiratory Fitness from Baseline to Post-Intervention
Tidsramme: From baseline to post-operative visit (approximately week 9)
|
Assessed by VO2peak by a graded maximal (or submaximal if equipment is unavailable) cycle exercise stress test. VO2peak is defined as the highest values of oxygen uptake averaged among every 30-second interval during the test. VO2peak will be reported in both relative (ml·kg-1·min-1) and absolute (L/min) terms. |
From baseline to post-operative visit (approximately week 9)
|
|
Change in Short Physical Performance Battery (SPPB) Score from Baseline to Post-Intervention
Tidsramme: From baseline to post-operative visit (approximately week 9)
|
Assessed by the Short Physical Performance Battery (SPPB) which is comprised of three sections: 1) balance with feet together, semi tandem, and full tandem is held for up to 10 seconds with no support and measure in seconds. Scores are summed for the measure of balance for a range of 0 to 30 seconds; 2) usual gait speed over four meters is timed (seconds); and 3) chair stand where the time(s) to complete five chair sit-to-stands is recorded. Each of the three performance measures is assigned a score ranging from 0 to 4, with 4 indicating highest level of performance and 0 indicating inability to complete test. A summary score ranging from 0 (worst performers) to 12 (best performers) is calculated by adding walking speed, chair stands and balance scores. |
From baseline to post-operative visit (approximately week 9)
|
|
Change in Muscle Strength from Baseline to Post-Intervention
Tidsramme: From baseline to post-operative visit (approximately week 9)
|
The 1RM (repetition maximum) will be estimated from 10RM muscle strength tests on two exercises: 1) leg press, 2) chest press. 1RM values will be calculated and reported using validated equations. |
From baseline to post-operative visit (approximately week 9)
|
|
Change in Height from Baseline to Post-Intervention
Tidsramme: From baseline to post-operative visit (approximately week 9)
|
Height will be measured using a stadiometer, rounding up to the nearest 0.1 cm |
From baseline to post-operative visit (approximately week 9)
|
|
Change in Weight from Baseline to Post-Intervention
Tidsramme: From baseline to post-operative visit (approximately week 9)
|
Assessed by weight, rounding up to the nearest 0.1 kg. |
From baseline to post-operative visit (approximately week 9)
|
|
Change in Waist Circumference from Baseline to Post-Intervention
Tidsramme: From baseline to post-operative visit (approximately week 9)
|
Waist circumference will be measured, rounding up to the nearest 0.1cm. |
From baseline to post-operative visit (approximately week 9)
|
|
Change in Hip Circumference from Baseline to Post-Intervention
Tidsramme: From baseline to post-operative visit (approximately week 9)
|
Hip circumference will be measured, rounding up to the nearest 0.1cm. |
From baseline to post-operative visit (approximately week 9)
|
|
Change in Body Mass Index from Baseline to Post-Intervention
Tidsramme: From baseline to post-operative visit (approximately week 9)
|
Body composition will be assessed via bioelectrical impedance using a validated device. The device will estimate body fat using an algorithm based on participant age, sex, height, and body weight. |
From baseline to post-operative visit (approximately week 9)
|
|
Change in Nutritional Status from Baseline to Post-Surgery (Group A)
Tidsramme: From baseline to postoperative visit, up to 9 weeks
|
Assessed by the Perioperative Nutrition Score (PONS), a validated screening questionnaire that assists in determining risk of malnutrition in the perioperative setting. This is assessed via 1) Body mass index (BMI), which can be calculated through the participant's anthropomorphic measurements, 2) self-reported unplanned changes in weight or decrease in dietary intake, or 3) preoperative albumin level. |
From baseline to postoperative visit, up to 9 weeks
|
|
Change in Nutritional Status from Baseline to Post-Surgery (Group B)
Tidsramme: From baseline to postoperative visit, up to 9 weeks
|
Assessed by the Perioperative Nutrition Score (PONS), a validated screening questionnaire that assists in determining risk of malnutrition in the perioperative setting. This is assessed via 1) Body mass index (BMI), which can be calculated through the participant's anthropomorphic measurements, 2) self-reported unplanned changes in weight or decrease in dietary intake, or 3) preoperative albumin level. |
From baseline to postoperative visit, up to 9 weeks
|
|
Change in Quality of Life from Baseline to Post-Surgery (Group A)
Tidsramme: From baseline to postoperative visit, up to 9 weeks
|
Assessed by the European Organization for Research and Treatment of Cancer's (EORTC's) Quality of Life (QOL) core questionnaire (QLQ C-30), a validated, 30-item instrument designed to quantify and measure QOL in cancer participants. Questions are rated on a four point scale from 1 "Not at all" to 4 "Very much. All items have a score range from 0 to 100 points. A higher score represents better function and a higher quality of life. |
From baseline to postoperative visit, up to 9 weeks
|
|
Change in Quality of Life from Baseline to Post-Surgery (Group B)
Tidsramme: From baseline to postoperative visit, up to 9 weeks
|
Assessed by the Pittsburgh Sleep Quality Index (PSQI), a 19 question measure of 7 domains of sleep quality and patterns of sleep. The 19 self-rated items are combined to form 7 component scores, each of which has a range of 0 to 3 points with a 0 indicating no difficulty and 3 indicating severe difficulty. The 7 component scores are added to yield a total score with a range of 0 to 21 points. A total score of 5 or greater is indicative of poor sleep quality. |
From baseline to postoperative visit, up to 9 weeks
|
|
Change in Pittsburgh Sleep Quality Index (PSQI) Score from Baseline to Post-Surgery (Group A)
Tidsramme: From baseline to postoperative visit, up to 9 weeks
|
Assessed by the Pittsburgh Sleep Quality Index (PSQI), a 19 question measure of 7 domains of sleep quality and patterns of sleep. The 19 self-rated items are combined to form 7 component scores, each of which has a range of 0 to 3 points with a 0 indicating no difficulty and 3 indicating severe difficulty. The 7 component scores are added to yield a total score with a range of 0 to 21 points. A total score of 5 or greater is indicative of poor sleep quality. |
From baseline to postoperative visit, up to 9 weeks
|
|
Change in PSQI Score from Baseline to Post-Surgery (Group B)
Tidsramme: From baseline to postoperative visit, up to 9 weeks
|
Assessed by the Pittsburgh Sleep Quality Index (PSQI), a 19 question measure of 7 domains of sleep quality and patterns of sleep. The 19 self-rated items are combined to form 7 component scores, each of which has a range of 0 to 3 points with a 0 indicating no difficulty and 3 indicating severe difficulty. The 7 component scores are added to yield a total score with a range of 0 to 21 points. A total score of 5 or greater is indicative of poor sleep quality. |
From baseline to postoperative visit, up to 9 weeks
|
|
Change in Clinical Frailty Scale (CFS) Score from Baseline to Post-Surgery (Group A)
Tidsramme: From baseline to postoperative visit, up to 9 weeks
|
Assessed by the Clinical Frailty Scale (CFS), which consists of 9 questions assessing specific domains including comorbidity, function, and cognition to generate a frailty score ranging from 1 (very fit) to 9 (terminally ill). |
From baseline to postoperative visit, up to 9 weeks
|
|
Change in Clinical Frailty Scale (CFS) Score from Baseline to Post-Surgery (Group B)
Tidsramme: From baseline to postoperative visit, up to 9 weeks
|
Assessed by the Clinical Frailty Scale (CFS), which consists of 9 questions assessing specific domains including comorbidity, function, and cognition to generate a frailty score ranging from 1 (very fit) to 9 (terminally ill). |
From baseline to postoperative visit, up to 9 weeks
|
|
Length of Hospitalization Post-Surgery (Group A)
Tidsramme: 30 Days
|
Defined as the number of days of hospitalization post-surgery. |
30 Days
|
|
Length of Hospitalization Post-Surgery (Group B)
Tidsramme: 30 Days
|
Defined as the number of days of hospitalization post-surgery. |
30 Days
|
|
Time To Return of Bowel Function Post-Surgery (Group A)
Tidsramme: 30 Days
|
Defined as the number of days to a return of bowl function post-surgery. |
30 Days
|
|
Time To Return of Bowel Function Post-Surgery (Group B)
Tidsramme: 30 Days
|
Defined as the number of days to a return of bowl function post-surgery. |
30 Days
|
|
Discharge Disposition (Group B)
Tidsramme: 30 Days
|
Defined as participant disposition post-surgery: discharge to home, inpatient rehabilitation facility, or other. Data will be summarized using descriptive statistics. |
30 Days
|
|
Discharge Disposition (Group A)
Tidsramme: 30 Days
|
Defined as participant disposition post-surgery: discharge to home, inpatient rehabilitation facility, or other. Data will be summarized using descriptive statistics. |
30 Days
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Jeffrey Meyerhardt, MD, MPH, Dana-Farber Cancer Institute
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 24-384
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD-delingstidsramme
Data can be shared no earlier than 1 year following the date of publication
IPD-delingsadgangskriterier
Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .